Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016874 · ClinicalTrials.gov registry record · Phase 1
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00016874 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Vion Pharmaceuticals. The trial reports 2 study locations across 1 state.
The verdict
NCT00016874, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP, cisplatin, and paclitaxel in treating patients who have advanced or metastatic cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG triapine
Study Locations (2)
New York
- New York Presbyterian Hospital - Cornell Campus - New York
- Albert Einstein Comprehensive Cancer Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016874
The ClinicalTrials.gov registry entry for NCT00016874 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00016874 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00016874 about?
NCT00016874 is a clinical study titled "3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP, cisplatin, and paclitaxel in treating patients who hav...
What is the current status of trial NCT00016874?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-12. Estimated completion is 2008-01.
What conditions does trial NCT00016874 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00016874?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00016874?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00016874 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.